obesity-middle-east-2018-posters

6 / 7

Page 50
conferenceseries.com
Volume 8 Journal of Obesity & Weight Loss Therapy Obesity Middle East 2018
June 25-26, 2018
June 25-26, 2018 Dubai, UAE
Middle East Obesity, Bariatric Surgery
and Endocrinology Congress
The impact of obesity on seminal fluid in patients with male infertility
Ahmed T Alahmar, Zahraa Ali, Zahraa Muhsin and Hadeel Qasim
University of Babylon, Iraq
Aim: Data on the effect of obesity on seminal fluid and men fertility are inconsistent. The aim of this study was to evaluate the
impact of Body Mass Index (BMI) on semen characteristics.
Method: A cross-sectional study was conducted on 74 infertile men. Semen sample were collected and sperm concentration,
progressive motility, total motility and normal sperm morphology were assessed in accordance with WHO 2010 criteria. For
each patient weight and height were measure and patients were divided by BMI into normal weight (BMI: 18.5-24.9 kg/m2,
n=30), overweight (BMI: 25-29.9 kg/m 2, n=30) and obese (BMI: ≥30 kg/m2, n=14). Seminal fluid parameters were compared
among the three groups.
Result: Although sperm concentration was lower in obese men, sperm concentration, progressive and total motility and normal
sperm morphology did not significantly differ among normal weight, overweight and obese groups (P>0.05).
Conclusion: Our findings suggest that BMI may have no influence on sperm concentration, motility and normal morphology
in infertile men.
J Obes Weight Loss Ther 2018, Volume 8
DOI: 10.4172/2165-7904-C3-064
The therapeutic effects of matrine forMCD-induced NASH are associated with upregulation of HSP72
and suppression of mTOR
Ali Mahzari, Songpei Li, Xiu Zhou, Xiaoyi Zeng, Sherouk Fouda, Stephen Robinson and Jiming Ye
RMIT University, Australia
Non-Alcoholic Steatohepatitis (NASH) is an advanced stage of the metabolic syndrome in liver with serious consequences
largely because of hepatic injury, inflammation and fibrosis. Matrine (MW: 248) is used as a prescribed hepatoprotective
drug in humans and it has been shown by us to decrease hepatosteatosis and glucose intolerance in high fat-fed mice. Here, we
investigated whether matrine exerts therapeutic efficacy for NASH by attenuating hepatic injury, inflammation and fibrosis.
The study was performed in Methionine Choline-Deficient (MCD) diet-fed mice for 6 weeks with or without the treatment
with matrine (100 mg/kg/d). Compared with untreated MCD-fed mice, matrine markedly reduced hepatic injury (indicated
by ALT level, p<0.05), inflammation (indicated by TNFα, CD68 and inflammasome NLRP3, all p<0.05). Along with these
effects, matrine inhibited MCD-induced increases in fibrogenesis (as indicated by the expression levels of TGFβ, Smad3 and
type-I collagen (all p<0.05). Further examination revealed that matrine resecured MCD-suppressed Heat Shock Protein 72
(HSP72, a protective chaperon protein against cell toxicity) and inhibited MCD-activated mTOR (a key master regulator
triggering pathogenic pathways leading to NASH). Our findings indicate that matrine attenuated MCD-induced NASH by a
new mechanism involving the upregulation of HSP72 and inhibition of mTOR. This hepatoprotective drug may be repurposed
for the treatment of NASH.